Research Solutions Q1 Fiscal 2027 Earnings Call - AI Reads Double to 33 Million, $1M ARR Deal Signals Enterprise Traction
Summary
Research Solutions delivered a mixed first quarter, with total revenue dipping to $11.9 million as transaction revenue fell 8%, but platform subscription revenue grew 3.7% and gross margins expanded 300 basis points to 53.6%. The company's AI narrative is gaining momentum: AI reads of research papers doubled to 33 million since the last call, AI-related ARR jumped 38% sequentially to $1.1 million, and 49 business customers now have AI access in their contracts. A landmark $1 million ARR deal, the largest Scite deal in company history, closed just after quarter-end, and the pipeline exceeds $5 million in ARR. Management remains focused on fixing churn, which has improved 30% from its peak but still offsets strong upsell activity, while investing in agentic AI capabilities that allow researchers to purchase articles directly through assistants like ChatGPT and Copilot.
Key Takeaways
- AI reads of research papers doubled to more than 33 million since the last call, up from 16 million in September, showing rapid adoption of AI assistants in research workflows.
- B2B AI-related ARR reached approximately $1.1 million, up 38% sequentially from Q4 FY 2026, with 49 business customers now having AI access written into their contracts, up from 42 last quarter.
- The company closed a $1 million ARR deal last week, the largest Scite deal in its history, an expansion of an existing Article Galaxy contract; management sees it as replicable with several six- and seven-figure opportunities in the pipeline.
- Total pipeline is now well over $5 million in ARR, stronger than at any point in company history, according to CEO Roy Olivier.
- Total revenue fell to $11.9 million from $12.3 million a year ago, as transaction revenue declined 8% on lower paid order volume, partially offset by 3.7% growth in platform subscription revenue.
- Gross margin expanded 300 basis points to 53.6%, driven by a revenue mix shift toward the higher-margin platform business (now 44.6% of total revenue) and improved transaction margins (26.7% vs. 23.8%).
- Adjusted EBITDA was $1 million, or 8.6% margin, down from $1.5 million a year ago due to higher G&A costs (including severance and legal) and increased technology investment; excluding one-time items, adjusted EBITDA was about $1.5 million.
- Churn remains the biggest pain point but has improved about 30% from its peak after implementing Gainsight and reorganizing the renewal team; recent quarterly churn has been consistent at about $300,000.
- Researchers at more than 15 corporate customers, including several Fortune 500 enterprises, completed hundreds of article and rights orders through AI assistants in October, up from a few dozen per month over the summer.
- The company launched an MCP for Microsoft Copilot, supporting both Scite and Article Galaxy, and is now available inside ChatGPT, Copilot, and Claude, meeting researchers where they work.
- Scite released a completely new AI research assistant that searches literature, clinical trials, drug safety data, patents, grants, and the open web, with every answer grounded in verified, retraction-checked citations.
- Publishers are shifting from asking whether to allow AI access to their content to asking how to get paid for it; Research Solutions is using its AI reads reporting to deepen publisher relationships and negotiate metered reads.
- Operating cash flow was $1.2 million, and the company ended the quarter with $12.6 million in cash and no long-term debt, even after funding $1.2 million of Scite earnout payments.
- Management expects full-year EBITDA to be slightly lower than previously guided due to a delayed large deal and non-recurring costs, but expects the run-rate to increase and potentially exceed prior targets.
- The company added 22 net new platform deployments in the quarter, bringing total deployments to 1,298, with total active customers rising to 1,360.
- CEO Roy Olivier said the board is in 'violent agreement' that buying back shares at current prices is arguably the best use of cash, and an announcement could come when definitive.
Full Transcript
Leslie, Conference Operator, Research Solutions: Good morning, everyone, and thank you for participating in today’s conference call to discuss Research Solutions’ financial and operating results for its fiscal 2027 first quarter ended September 30, 2026. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. John Beisler, Investor Relations. Please go ahead.
John Beisler, Investor Relations, Research Solutions: Thank you, Leslie, and good morning, everyone. Welcome to the Research Solutions first quarter fiscal year 2027 earnings call. With me today are Roy W. Olivier, Chairman and Chief Executive Officer, Dave Kutil, Chief Financial Officer, and Josh Nicholson, Chief Strategy Officer. After the market closed yesterday afternoon, the company issued a press release announcing its results for the first quarter of fiscal 2027. The release is available on the company’s website at researchsolutions.com. Before management begins their prepared remarks, I would like to remind you that some of the statements made today will be forward-looking and made under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those expressed or implied due to a variety of factors.
We refer you to Research Solutions’ recent filings with the SEC for a more detailed discussion of the risks that could impact the company’s future operating results and financial condition. Also on today’s call, management will reference certain non-GAAP financial measures, which we believe provide useful information for investors. A reconciliation of these measures to GAAP measures is included in the earnings press release issued yesterday afternoon. Finally, I would like to remind everyone that this call will be recorded and made available for replay via a link on the company’s website. I would now like to turn the call over to Roy W. Olivier. Roy?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thank you, John. As we continue to develop our next-generation AI-based research tools, we watch a few key metrics that ensure we’re on track to that objective. We believe that publisher participation and customer adoption are two of the critical metrics, and we saw nice progress in Q1, offset by weakness in our B2C and DocDel business. While churn is not where we want it to be, we did see a slight improvement during Q1. Our B2B AI-related sales were up 38% sequentially from Q4 FY 2026. As reported last week, we closed a $1 million ARR deal last week and continue to see a number of five-figure, six-figure, and some seven-figure opportunities in our pipeline. We do have a stronger pipeline than at any time in the past. It’s currently well over $5 million in ARR.
In my mind, these early indicators reinforce that we’re on the right path. We did launch an MCP for Copilot, supporting both Scite and Article Galaxy functionality. A researcher can interact with any supported LLM, then ask that LLM to go get those documents, and Article Galaxy will go get them in a copyright-compliant way. We’re continuing to see strong adoption and interest of the previously released Claude, Enterprise, and ChatGPT solutions. As noted in our release, we continue to see nice expansion in our gross margins, even on lower revenue. After excluding for one-time events, primarily severance and legal costs, adjusted EBITDA was about $1.5 million. Operating cash flow was $1.2 million, and we continue to have a strong balance sheet with $12.6 million in cash and no long-term debt.
This puts us in a strong position to invest where we think we’ll see the biggest increase in shareholder value. I’ll hand the call over to Dave to walk through our fiscal first quarter financial results in more detail, and then I’ll come back with some comments and an outlook for the year ahead. Dave?
Dave Kutil, Chief Financial Officer, Research Solutions: Thank you, Roy. Good morning, everyone. I’ll start with the first quarter results and then cover cash flow and the balance sheet. Total revenue for the first quarter of fiscal 2027 was $11.9 million, compared to $12.3 million in the first quarter of fiscal 2026. This increased platform revenue was more than offset by a decrease in transaction revenue. Our platform subscription revenue increased 3.7% to $5.3 million, compared to $5.1 million in the prior year quarter. The growth was driven by an increase in B2B platform ARR due to a mix of new logo generation and upsells and cross-sells into our existing customer base, partially offset by a decline in B2C ARR. We added 22 net new platform deployments in the quarter, bringing total deployments to 1,298 at quarter end.
We ended the quarter with $22.5 million in annual recurring revenue, up 5.7% year-over-year, which breaks down as approximately $16.5 million in B2B ARR and approximately $6 million in normalized ARR associated with Scite’s B2C subscribers. B2B ARR grew $1.7 million, or 11.5%, versus the year-ago period. In the quarter, net B2B ARR increased approximately $257,000, while normalized B2C ARR declined approximately $299,000. B2B ARR included AI-related ARR of approximately $1.1 million, up 38% from the end of fiscal 2026. Please see yesterday afternoon’s press release for how we define and use annual recurring revenue and other non-GAAP terms. Transaction revenue for the first quarter was approximately $6.6 million, compared to $7.2 million in the prior year quarter, a decline of approximately 8%, primarily reflecting lower paid order volume.
Our total active customer count for the quarter was 1,360 compared to 1,326 in the same period a year ago, with growth in academic customers more than offsetting a decline in corporate customers. Consolidated gross margin for the first quarter was 53.6%, a 300 basis point improvement over the first quarter of fiscal 2026. The increase is due to the ongoing revenue mix shift towards our higher margin platform business, which now represents 44.6% of our total revenue, along with higher transaction margins. Gross profit dollars grew 2.5% to $6.4 million despite the lower revenue base. The platform business recorded gross margin of 87% compared to 88.1% in the prior year quarter, reflecting slightly higher hosting and technology costs. Gross margin in our transactions business was 26.7% compared to 23.8% in the prior year quarter, a 280 basis point improvement.
The increase was primarily attributable to improved margins on our copyright content, reflecting favorable publisher mix and pricing. Total operating expenses in the quarter were $5.5 million compared to $5.3 million in the prior year quarter. Higher general and administrative expenses, primarily severance and legal costs, and higher technology and product development spending were partially offset by lower sales and marketing expense and a non-cash recovery of stock-based compensation resulting from forfeitures. Other expense for the quarter was $56,000 compared to $191,000 in the prior year quarter, primarily reflecting lower cash accreted interest on the Scite earnout liability. As a reminder, as of November 2nd, we have completed six of the eight quarterly Scite earnout payments. Net income for the quarter was $765,000 or $0.02 per diluted share compared to $749,000 or $0.02 per diluted share in the prior year quarter.
Adjusted EBITDA for the quarter was $1 million or an 8.6% margin compared to $1.5 million for the first quarter of last year. The decrease reflects higher general and administrative costs and increased technology investment, partially offset by higher gross profit and lower sales and marketing expenses. Turning to cash flow. Cash flow from operations for the first quarter of the fiscal year was approximately $1.2 million compared to approximately $1.1 million in the prior year quarter, helped by the timing of vendor payments. Turning to our balance sheet, cash and cash equivalents as of September 30th, 2026 were $12.6 million, essentially unchanged from June 30th, 2026, even after funding $1.2 million of cash Scite earnout payments during the quarter. There were no outstanding borrowings under our $500,000 revolving line of credit, and we have no long-term debt.
With a solid cash position and no debt, our balance sheet gives us the flexibility to complete the remaining Scite earnout payments in fiscal 2027, while at the same time continuing to invest in the business. I’ll now turn the call over to Josh. Josh?
Josh Nicholson, Chief Strategy Officer, Research Solutions: Thanks, Dave. Good morning, everyone. Today I want to cover four things this quarter: how fast AI usage is growing, how it’s showing up in our customer contracts, and how researchers and their agents are starting to buy content from us through their AI assistants, and then the product work behind all of it. First, AI usage keeps growing fast. Since February, we’ve counted every time an AI assistant like Claude, ChatGPT, or Copilot reads a research paper through us. At our last call in September, that was 16 million papers. Today, it’s more than 33 million. It doubled in about two months, and as Roy mentioned, we’re now available inside ChatGPT and Microsoft Copilot, as well as Claude. The researchers can reach our tools from whichever assistant their company uses. Second, AI is showing up in our business customers’ contracts. Dave gave you the AI-related ARR figure.
Behind it, 49 business customers now have AI access written into their contracts, up from 42 last quarter. Most are existing customers adding AI access when they renew or expand, and when they do, the contract typically gets meaningfully bigger. This quarter, we also closed the largest Scite deal in our history, an expansion of an existing Article Galaxy contract. That is the thesis we had on day one, bringing Scite into Research Solutions, and a big thank you to our sales team for the work to get it done. Third, researchers are starting to buy through their AI assistants. There’s been a lot of talk this earnings season about AI agents making purchases. A few weeks ago, Uber said AI agents booked about 500 orders, 500 food orders, and four rides over Halloween week, out of more than 300 million trips and orders.
DoorDash said agents had placed several hundred orders in total. The consumer world is still waiting for agent-driven buying to take off. In our world, researchers are already buying this way. Since September, a researcher at a corporate customer can ask their AI assistant to get a paper, see the price, they buy it, and then the order is placed on their company’s account and delivered to the user with the copyright cleared. In October, researchers at more than 15 corporate customers, including several Fortune 500 enterprises, completed hundreds of articles and rights orders through their AI assistants and agents, up from a few dozen a month over the summer. It’s still a small share of our total orders, but it’s growing fast, and it’s a real business purchasing on invoice through existing accounts. We think research is one of the first places AI-assisted buying works for a simple reason.
About half of these assistants want to read is behind a paywall. When the assistant hits that wall, it needs a compliant way to get the paper and wherewithal. We have the publisher agreements, the pricing, and the rights built up over 20 years. Fourth, a new Scite assistant and what else we shipped. The biggest launch on Scite side is a completely new version of our AI research assistant. It brings everything we built for AI assistants like Claude and ChatGPT into our own product with additional research-focused functionality layered on top. A researcher can now search the literature and read full papers, but also clinical trials, drug safety data, patents, and grants, plus the open web and gray literature, and upload their own files and work with them.
Every answer is grounded in real cited sources, and it checks whether those citations are real and whether papers have been retracted. It became the default for individual users in October and is rolling out to all our institutional customers now. We also gave enterprise administrators a dashboard to see and manage how their organization uses AI. On the Article Galaxy side, we opened AI access to all Article Galaxy customers, built ordering into AI assistants as I described, made it simpler to buy the rights to use an article with AI, and overhauled our reference manager. We also brought Scite inside Article Galaxy, so open access papers come in automatically. On the publisher side, our AI reads reporting now shows publishers which of their journals AI assistants are reaching for and how often they’ve turned away at a paywall. That has changed our conversations with them.
A year ago, publishers asked whether to let AI near their content. Now they ask how to get paid when it is. We’re talking with many of the publishers we worked with for 20 years about what comes next and are excited about the progress on that front. To sum up, AI usage doubled since the last call, more business customers are building it into their contracts, researchers are already buying articles through their AI assistants, and publishers want to work with us on it. AI isn’t going to around us. It’s coming through us. Over to you, Roy.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thanks, Josh and Dave. Thanks everyone for joining us. To close, just three points. First, as Josh said, AI is coming through us, not around us. AI reads of research papers have doubled to more than 33 million since our last call. 49 million business customers now have AI access in their contracts. I’m sorry, 49 business customers have AI access through their contracts. And our pipeline’s over $5 million in ARR, stronger than at any point in our history. Second, it’s showing up in the numbers. B2B ARR grew 11.5% to $16.5 million. Total ARR reached $22.5 million, and gross profit grew 2.5% or 300 basis points to 53.6% as platform grew to 45% of revenue. Third, we’re doing this from a position of strength.
$1.2 million of operating cash flow, $1.2 million paid toward the Scite earnout, and still $12.6 million in cash at quarter end with no long-term debt. We look forward to updating you further in February. With that, I’d like to turn it over to the operator for Q&A. Operator?
Leslie, Conference Operator, Research Solutions: Thank you. If you would like to ask a question at this time, please press star one on your telephone keypad. To leave the queue at any time, please press star two. Once again, that is star one to ask a question. We will take our first question from Jacob Stephan with Lake Street Capital Markets. Please go ahead.
Jacob Stephan, Analyst, Lake Street Capital Markets: Great. Thanks. Maybe just first for me on the B2B side of things. I guess if you could kind of help us think through what gross bookings were in a quarter versus kind of churn dollars and any additional comments that you have on churn and what you kind of see as we look forward here would be helpful on the B2B side.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Sure. Dave, you want to take that?
Dave Kutil, Chief Financial Officer, Research Solutions: Yeah, sure. We had about $500,000 in new bookings. Look at our run rate the last few quarters, it has been a little choppy. The third quarter they reported last year was about $1.3 million for the year-end quarter. Like I said, the choppiness kind of continues, but with the deal that we announced last week, that will be in this coming quarter. We expect that to be strong. From a churn perspective, we are pretty much now on a nice run rate. Not exactly where we would like it to be, but compared to about a year ago when we kind of did the all-hands-on-deck churn analysis, put in Gainsight, we have come down about 30% from that. A look at the last three quarters, the trend has been pretty consistent of about $300,000 of churn.
Again, not where we want to be, but some very significant improvement from when we decided to put in Gainsight and take all those strategic actions.
Jacob Stephan, Analyst, Lake Street Capital Markets: Got it. Maybe just on the large deal that you guys announced, could you maybe talk about just what the term is there and how that’s billed comparison to maybe some of the smaller Scite deals that you have?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: It’s a one-year deal, but it has a significant upside as we move into year two and three. It’s the same terms as a normal agreement. I mean, it’s, I believe, correct me if I’m wrong, Dave, platform upfront.
Dave Kutil, Chief Financial Officer, Research Solutions: Correct.
Jacob Stephan, Analyst, Lake Street Capital Markets: Okay, got it. Then I just wanted to ask on the transaction side of things. Your active customers continue to grow. Revenue obviously is continuing to be a little soft, but I guess that implies that orders per customer are falling. Is that more agentic AI kind of substituting for the document buys or any budgets? Maybe, what do you see in terms of the results stabilizing in the transaction segment?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Yeah, we continue to see kind of single-digit year-over-year declines in DocDel. Most of that is really driven by customer churn, a couple of customers that we churned out that are still kind of headwind to us in year-over-year growth. But we are seeing some other weakness, which we are not 100% sure why. It could be agentic AI. It could be just a phase in the research cycle. We can see it, but when we talk to customers about it is about, "Why is yours in particular down?" We do not really get super specific answers about why they are down, because they just have research cycles, and sometimes they are up and sometimes they are down. But Josh, you may have some additional color on that.
Josh Nicholson, Chief Strategy Officer, Research Solutions: Yeah, I do not have too much to kind of add to what Roy said. I think we are seeing better usage of the product. There is more search, there is more engagement. There is more access through tokens and subscriptions. And I think, again, there is more purchases now happening through this new mechanism of the agents than ever before. And so, I still think a lot of this is somewhat of a hangover of losing one very large, massive account. Roy and I go back a little bit between each other. Is there the zero-click phenomenon? Is it not? And so, that is certainly a possibility. There are less clicks throughout the web and more generally. And so, it certainly could be. But I do think there is the potential for the agentic kind of consumption to increase and to be a meaningful line for DocDel. But it is still quite early days there.
Jacob Stephan, Analyst, Lake Street Capital Markets: Okay. Thanks, guys.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thank you.
Dave Kutil, Chief Financial Officer, Research Solutions: Thank you.
Leslie, Conference Operator, Research Solutions: Thank you for your question. We will take our next question from Derek Greenberg with Maxim Group. Please go ahead.
Derek Greenberg, Analyst, Maxim Group: Hi, good morning. I wanted to first ask just about some of the outlook you provided on the last call, if there’s been any material change or if you kind of see it as still your expectations for the year. It was for continued growth in corporate and academic B2B, B2C roughly flat year-over-year, transactions down low single digits, which I think you just kind of mentioned, and then improved adjusted EBITDA and cash flows.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Dave, any updates on that?
Dave Kutil, Chief Financial Officer, Research Solutions: Yeah, from a B2B perspective, the timing of the large deal from when we last talked at year-end pushed out a little bit. So that will have an impact on top-line sales, obviously not ARR, but top-line sales, and that will flow through to EBITDA. It’s not a huge amount. And remember, going forward, we’re looking to build on that, and the MCP-related ARR that we talked about will continue to grow. But the B2C number that we said was flat, we expected the quarter to kind of play out like it did, and it was right on our budgeted number. We do see an uptick there to start this second quarter. It’s persisting.
We’re right in the middle of the quarter, so there perhaps may be a little bit of upside there, but we like to conservatively look at that because it’s very cyclical, and the winter break can sometimes disrupt that momentum. But we’re optimistic with what we’re seeing there. On the EBITDA side and the expense side, nothing really has changed from a cost structure standpoint. And what we’re really happy with is the flow-through that we’re seeing on the gross profit line. That has really been a strong portion that we’ve talked about quarter after quarter, but you can really see with our gross margins right now in 53%+ that’s also flowing through the bottom line.
Given that there’s been a few items here from a cost standpoint that are more non-recurring in nature and not part of our cost base going forward, we’re very optimistic for the future. But this quarter obviously was impacted by the delay in the new booking there, and then some non-recurring spend as well. So the full year probably from an EBITDA perspective is going to be a little lower than the last time we talked, but from a run rate standpoint, EBITDA will continue to increase and probably even above what we talked about in the last conference call.
Derek Greenberg, Analyst, Maxim Group: Yeah, thank you. That’s really helpful. And then just on your sales force, I was wondering how you’re feeling about the changes you’ve made over the past year or so, and maybe if you could talk about the performance of the different teams, new logos versus upsell, renewal, and any other color you want to provide.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Yeah, I mean, we continue to see very strong activity pipeline and results in the corporate team. They are doing an amazing job. Academic team is doing a nice job. They have got a new leader. We have had some new headcount in that group, so they have had a little bit slower start than the corporate team. The renewal upsell team continues to do, I would describe it as a pretty good job on the upsell side, but it is still being offset too much by churn. So, I am happy to see we are seeing some slight improvement in churn based on the investments we made six, nine months ago in Gainsight.
As I explained in the last call, we reorganized that group, added some additional people in that group to reduce the number of accounts per rep, which we think will pay off with better coverage and better customer communication in the coming quarters. As we continue to see improvement in the churn side, we will continue to see net ARR growth grow pretty significantly, because as I said, they do a nice job with upsells, just churn continues to be, in my opinion, our biggest pain point.
Derek Greenberg, Analyst, Maxim Group: Okay, that makes sense. Last one from me, just on sales cycles. I was wondering if you are seeing any material change from maybe where you have been historically, just given larger deal sizes or adding in the AI component?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: I am sorry, what was the first part of the question? In what cycle?
Derek Greenberg, Analyst, Maxim Group: Sales cycles.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Oh. Yeah, we continue to have a pretty quick sales cycle. I mean, it’s typically two, three months. A significant percentage of what we closed in the quarter was actually a deal generated during that quarter. However, these larger deals are taking longer. So the $1 million deal we did a press release on, that had been a heads-down, a lot of people working on a deal for a year. So, it comes down to deal size in a lot of cases. We still do a lot of smaller deals, and those are typically pretty quick sales cycles. But as we get into, I mentioned, or I was going to mention, I think we did a $70,000 deal day before yesterday, did a $100,000 deal, I think, last month, and then the $1 million deal. Those take a little bit longer.
Those were typically working five, six, seven months to get them through all of the various approval levels, AI review, software tech, IT reviews. So smaller deals continue to be in that two to three month range. Larger deals stretch it out a bit. But ASP goes up, which was nice.
Derek Greenberg, Analyst, Maxim Group: Okay, got it. Well, thanks for taking my questions, guys.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thank you.
Josh Nicholson, Chief Strategy Officer, Research Solutions: Thanks.
Leslie, Conference Operator, Research Solutions: Thank you. We will take our next question from Richard Baldry with Roth Capital. Please go ahead.
Richard Baldry, Analyst, Roth Capital: Thanks. You look specifically at the large deal. You talk about how many peers or similarly scaled customers in terms of their own activities you would have in your user base, trying to figure about how replicable that is over the long term, and whether that was a large existing client that had been steadily expanding, or there was a material step-up maybe due to something like the increased AI functionality.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: We do not think that is a unique deal. We have other deals in the pipeline that are large, either in the six figures or even in the seven figures that are similar, and they are driven by, as these large corporations are trying to solve this problem of, "How do I connect these various silos? I have a bunch of subscriptions for content. I have a bunch of content I own. I have Article Galaxy maybe already installed or something like Article Galaxy installed. And how can I streamline this research process and take steps out of it?" And one of the other deals we are working on, which is a pharma company about the size of the million-dollar deal, that is also a seven-figure deal, and we are reducing their research kind of steps by 11 steps. And so when you spread that across thousands of researchers, it does speed up research.
It improves the quality of the output. We are pricing the product to the value that we are delivering. My point is, it is not a unique deal. The customer that signed the million-dollar deal, they have been a longtime customer on the Article Galaxy side, but I think the revenue is probably been flattish for five years or more. This is a material step-up because we can materially impact the number of steps and the amount of time it takes them to do a research project. That is kind of what we have been trying to build with being part of the infrastructure as opposed to being a plug-in here or there. Josh, if you have got any additional comments, go ahead.
Josh Nicholson, Chief Strategy Officer, Research Solutions: Yeah, no, I think it is very replicable. I think there is another kind of interesting aspect in this in that, it is not just that there is AI functionality, it is also who we are talking to in the organizations. AI budgets both across corporate and academic, I would say, are growing, whereas historically, library budgets and content budgets are kind of flat or decreasing. Involving new people into the conversation where these numbers are more of the norm certainly makes it easier to close that deal. I do think there are a whole host of AG customers that are decent-sized, have kind of been around, and I think there is big opportunity to expand them. I think they are used to these, right? This is a big deal for us, but it is probably a normal-sized license for a lot of these groups.
I think, again, this kind of gets back to the thesis from day one is like, "Hey, we have an innovative tool. We have a great customer base. Let us go into that customer base and expand." I think that is a mix of the AI, mix of the product, but really also a big testament to the sales team believing and knowing that, "Hey, this is not a one-off or an exceptional deal. This is something that we can do over and over if we take our time, follow the process, and to Roy’s point, involve a lot of different people, right? These deals do take a little bit longer. Product is heavily involved. There is more in-person visits. All those things play out and are well worth it.
I am certainly excited about some of the other deals that we are engaged in on the pipeline as well, because I think, again, we do not want this just to be a one-time PR. We want this to be kind of the new norm going forward. I think it certainly does reflect the value that we are bringing to these groups.
Richard Baldry, Analyst, Roth Capital: If I look at the transactions, gross margins, I looked at last year, it sort of started in the 24% zone, ended at 26%. Now you are just under 27%. Can you talk about the underlying trends that is improving that, how sustainable or extensible that could be?
Dave Kutil, Chief Financial Officer, Research Solutions: Yeah, I can take that one. We really feel like some of the actions we talked about two quarters ago are bearing fruit from not only, again, we talk a lot about the platform, transactions to platform transition, and that is still probably the biggest driving factor. But we also looked at transactions pricing as well, so we are seeing some of that impact. We are maintaining, like we have said we would, maintaining our cost structure when it comes to cloud storage and AI costs as well. So we are managing those very well. I think some of the savings projects, again, we referenced three quarters ago, are starting to bear fruit. So, it is really a confluence of all those events and strategies that make that margin, we think, pretty durable going forward.
Richard Baldry, Analyst, Roth Capital: Last for me, if we look at sort of the movements within the OPEX lines, R&D was up a bit. The one-time things, I think, impacted G&A, and sales and marketing was down. How much do you think the 1Q sort of run rates reflect what we see going forward? Or do we get back to more of like the stance we saw in the fourth quarter?
Dave Kutil, Chief Financial Officer, Research Solutions: I think it will be a little bit into the second quarter. But like I said earlier, it is not going to be part of our run rate cost structure in the long term, certainly. Some of the things I did not comment on the research and development technology side, we were doing for security purposes, IT security projects that have a kind of a six-month life cycle here. We will get those in place, and then those kind of one-time project costs will go away. We think then that supports everything that Josh and Roy were talking about these larger deals. They do take a lot more time, but they also bolster some of the IT security that we have. In concert with those actions, we will feel like we are in great shape.
The last thing I will say, sales and marketing, we probably will ratchet that up a bit. I have talked in prior calls about the spend level, being able to change that on a weekly basis. Because we are coming out of that kind of summer lull that we expected, and we are seeing some returns early in the build part of this quarter, we probably will turn the dial up a little bit on the advertising spend. So that is the one area where I would say we are probably a little lower, actually, in the first quarter of our fiscal year. Going forward, we will probably turn that up to the tune of another $100,000 or $200,000. But overall, the net run rate should be lower after we get through these projects and kind of one-time items.
Richard Baldry, Analyst, Roth Capital: Great. Thanks, and congrats on the big deal.
Dave Kutil, Chief Financial Officer, Research Solutions: Thanks.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thank you.
Leslie, Conference Operator, Research Solutions: Thank you once again. If you would like to ask a question, please press star one on your telephone keypad now. We will take our next question from Avi Fisher with Long Cast Advisors. Please go ahead.
Avi Fisher, Analyst, Long Cast Advisors: Hey, good morning. Thank you for taking my call. What would you say It sounds like you have more large deals in the hopper. I just wondered to gauge the probability or possibility of another $1 million-sized deal in the next 12 months or so.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: I do not know how to guess that. I would say it is probable. I cannot say whether it is 60% or 90%. We have some deals that are well down that path, with the longer sales path I described. One in particular looks very good. My experience doing elephant-type deals is never done till it is done, and there is 100 ways it can go sideways. I would not commit to it, but I think there is a good probability we will close something. When you say end of the year, I assume you are talking fiscal year, not calendar.
Avi Fisher, Analyst, Long Cast Advisors: Yes, of course. Can you talk a little bit about how this product, does it help your customers save money on token spend or just cut out steps in the process?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Yeah, Josh, you can touch the token spend, but the steps in the process is big there, because if you have 3,000, 4,000 researchers, all of whom are high-income people, reducing steps is a big financial impact on your cost structure, or your efficiency of the researchers. Josh, you want to touch on the token part of it?
Josh Nicholson, Chief Strategy Officer, Research Solutions: Yeah, it’s not really touching on kind of the token spend. If anything, in many of these kind of instances, they’re using their tokens and not our tokens to do this. I think it’s really the fact that they have a handful of different tools, their researchers, again, which can be in the hundreds or thousands, have to jump between these different tools, and then they have to do this process, often medical writing, thousands of times a year. So, those steps that Roy had mentioned as 11, if you really break it down to all the steps, it’s probably way more than that. So, it’s very clunky that they have, but they have to do certain things in certain ways.
So, really, if you use Article Galaxy and Scite together, it’s kind of a great one-two punch with AI to do things that still follows the regulatory steps that are necessary, but can help those humans cut down time, and in some cases, cut down even the human work. So, I think it’s really more about accelerating the time that the humans have to do, and yes, streamlining those workflows in, again, a copyright-compliant way. If you need to check the reuse rights for hundreds of different articles and you have to do those one at a time, that’s a huge pain, a lot of time. If you can do that all automatically, or even just at a glance, that alone is a big step in efficiency. So we see that across a variety of different steps.
Again, these calls are pretty fun to be in because you’re untangling these big, complex webs and providing a really nice solution to these groups.
Avi Fisher, Analyst, Long Cast Advisors: Yeah, and meeting the customer where they are. I guess given your ability to grow organically and then to innovate organically and to generate cash flow organically, how come you’re not aggressively buying back shares?
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Well, yeah, we have talked about that before. I think everybody on the board is in violent agreement that certainly where the share price is now, that is arguably the best use of cash. As soon as we can announce something on that that is more definitive, you will see it. It is not something we are doing today, but we agree that is a very, very good use of cash.
Avi Fisher, Analyst, Long Cast Advisors: All right. Thank you.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thank you.
Josh Nicholson, Chief Strategy Officer, Research Solutions: Thanks, Avi.
Leslie, Conference Operator, Research Solutions: Thank you for your question. We will take our next question from George Melas with MKH Management. Please go ahead.
George Melas, Analyst, MKH Management: Great. Thank you. Thanks for taking my question. Can you guys talk a little bit about publisher participation? Josh, you talked in your prepared remarks, you talked about how your relationship with publishers is getting deeper as you can show them more clearly which paper is read, which paper maybe people want to have access to but can’t because of paywall, and how is that changing the conversation with some of your publishers?
Josh Nicholson, Chief Strategy Officer, Research Solutions: Yeah. Across both products, we really want to be more strategic with publishers. We sit on a lot of very valuable data. What is being bought, what is being rented, what is being denied in AI, what is being used in AI. There’s a new standard called COUNTER that is used to determine the ROI or the value of subscriptions. Historically, that has been how do humans read content, right? How is it downloaded, how is it viewed, et cetera. COUNTER, as of the middle of October, put out new reports looking at agentic usage. We are pretty uniquely able to show that demand. We have a public page that shows this broken down by publisher, broken down by journals, allows journals or publishers or societies to get these metrics and then to talk to us.
That’s a very active area of focus for us, where we are talking to publishers regularly, going to more events, and then I would say evolving our current agreements that we have with them. These agreements with publishers can help publishers basically defend their subscription value in an AI world because we’re giving them the metrics. They can grow their subscription value, again, because we’re giving them the metrics. Or, and I think this is kind of the interesting area for some growth for both us and them, they can sell metered reads to their content into AI. There’s a host of a few different startups also working in this area. There’s some hosting agencies like Silverchair and Atypon also working in this area.
I think our big differentiators are our corporate customer base, which is by far the largest across anyone providing any sort of similar functionality, and the fact that we already have these established relationships of sending royalties to publishers. It is really nice narrative and data that we can show to publishers and say, "Hey, we want to work with you strategically to help bring your content into AI." I really do think how content is consumed is transformationally kind of changing. If you look at print to web to AI, I think on average people are reading maybe 20 articles a month. Now if you look at an AI, the AI is consuming 300 to 600 articles per month. It is just a dramatic increase in kind of the consumption because AI can read an article instantly versus a human spending hours.
That is a big part of our strategy, is getting these publishers on board, exposing more of their content with them, and then providing them strategic value through data and revenue so that they deeply engage with us. A lot more kind of on the pipeline. We put out one press release on MDPI, and hopefully there will be some more coming soon, highlighting the traction we have there.
George Melas, Analyst, MKH Management: Great. Okay. Lot to think about there. Maybe on the large transaction that you guys closed just a few weeks ago. How much is your content and access to publishers really important in that transaction, and how much is it really providing sort of the infrastructure to streamline their processes?
Josh Nicholson, Chief Strategy Officer, Research Solutions: Yeah. On that one, I think it is more kind of the latter. I think it is really the infrastructure there. Obviously, having good full-text search across all these publisher relationships matter a ton, but if we had lost one or two publishers there, I do not think it would have changed the deal at all. I think we talk a lot about strategy, and we are giving you these kind of complex metered reads and all these different things. In this case, I think it is pretty simple, right? There are large customers out there that have simple challenges, or maybe not simple challenges, large challenges. If we go in and leverage our longstanding relationship with them, we can show them, "Hey, here is how you can solve that." That is a mixture of AI, it is a mixture of our content relationships on both products.
I think, also a testament to the sales team, right? We have some people that can really go and across and do these enterprise deals versus kind of checking down at a smaller six-figure deals, right? It takes some patience. It is multi-stakeholder on both sides, their product and ours, and a lot of listening and, again, kind of going to where the user is. That, to me, is exciting because, again, we have a lot of very large customers, and in some cases, they are not paying the largest amount, right? That is an opportunity that I think we see.
George Melas, Analyst, MKH Management: Great. Thank you very much.
Josh Nicholson, Chief Strategy Officer, Research Solutions: Thanks, George.
Leslie, Conference Operator, Research Solutions: Thank you. At this time, there are no further questions in the queue. I would now like to turn our meeting back to Mr. Roy Olivier.
Roy W. Olivier, Chairman and Chief Executive Officer, Research Solutions: Thanks, everyone, for joining us on our call today. We look forward to speaking to you in February to discuss our second quarter FY 2027 results. Have a great day.
Leslie, Conference Operator, Research Solutions: Thank you. This brings us to the end of today’s meeting. We appreciate your time and participation. You may now disconnect.